There is therefore consistent evidence to suggest that there may be significant harm to patients with cancer who are treated with recombinant human erythropoietin.
ιπ και 6769 ασθενείς) παρατηρήθηκε σε ασθενείς που έλαβαν θεραπεία με ανασυνδυασμένη ανθρώπινη